Premium Content Regulatory alerts

EAMS scientific opinion: Avelumab in the treatment of bladder cancer

Study results show significant 7.1-month improvement in median overall survival with avelumab as first-line maintenance plus best supportive care (BSC) compared with BSC alone.

Please sign in or register for FREE

No comments yet.